Trial Profile
A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms NIVOPOSTOP
- 10 Mar 2022 Planned End Date changed from 1 Dec 2023 to 1 Sep 2027.
- 10 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Aug 2027.
- 04 Dec 2020 Prtocol amended to change dose of nivolumab from 360 to 240 mg given 3 weeks before RT-cisplastin and 480 mg nivolumab maintenance dose added.